ArticleFEBS open bio2020
Identifying the key genes and microRNAs in prostate cancer bone metastasis by bioinformatics analysis.
Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 51 citations in OpenAlex.
- Urinary miR-191-5p levels are significantly reduced after radical prostatectomy in patients with prostate cancer.Cancer cell international · 2026Article
- Knockdown of FOXD3-AS1 inhibits the progression of prostate cancer by targeting miR-491-5p/PEG10.Journal of cancer research and clinical oncology · 2025Article
- Identification of a ferroptosis related genes signature and GDF15 contributing to a new perspective for the diagnosis of CRPC.Scientific reports · 2025Article
- Matrix Remodeling Associated Genes (MXRAs): structural diversity, functional significance, and therapeutic potential in tumor microenvironments.Discover oncology · 2025Review
- Review
- Integrated machine learning algorithms reveal a bone metastasis-related signature of circulating tumor cells in prostate cancer.Scientific data · 2024Article
- Review
- The molecular and clinical role of Tensin 1/2/3 in cancer.Journal of cellular and molecular medicine · 2023Review
- Multi-omic profiling reveals an RNA processing rheostat that predisposes to prostate cancer.EMBO molecular medicine · 2023Article
- MicroRNAs in cancer metastasis: biological and therapeutic implications.Expert reviews in molecular medicine · 2023Review
- Unique microRNA expression profiles in plasmic exosomes from intrahepatic cholestasis of pregnancy.BMC pregnancy and childbirth · 2023Article
- Unlocking the predictive potential of long non-coding RNAs: a machine learning approach for precise cancer patient prognosis.Annals of medicine · 2023Review
- Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence.Frontiers in oncology · 2023Article
- The role of tensins in malignant neoplasms.Archives of medical science : AMS · 2023Article
- The role of AURKA/miR-199b-3p in hepatocellular carcinoma cells.Journal of clinical laboratory analysis · 2022Article
- The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone Microenvironment.International journal of molecular sciences · 2022Article
- Review
- PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate.Biomolecules · 2022Article
- KIF11: A potential prognostic biomarker for predicting bone metastasis-free survival of prostate cancer.Oncology letters · 2022Article
- Exosomes: Insights and therapeutic applications in cancer.Translational oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate adenocarcinoma (PCa) is the most common cause of death due to malignancy among men, and bone metastasis is the leading cause of mortality in patients with PCa. Therefore, identifying the causes and molecular mechanism of bone metastasis is important for early detection, diagnosis and personalized therapy. In this study, we systematically analyzed molecular correlates of bone metastasis by bioinformatics analysis. A total of 12 differentially expressed microRNAs (miRNAs) and 102 differentially expressed genes were identified. Five miRNAs had prognostic significance in biochemical recurrence-free survival (miR-636, miR-491-5p, miR-199b-5p, miR-199b-3p, miR-28-3p). The differentially expressed genes were significantly enriched in extracellular matrix, cell-substrate adhesion, collagen and integrin. Seven hub genes (VCAN, COL3A1, COL1A1, APOE, COL1A2, SDC1, THY1) with worse biochemical recurrence-free survival and one hub gene (MMP9) with worse overall survival were detected. miR-636, a novel oncogene, was found to be up-regulated in bone metastatic PCa tissues and also predominately up-regulated in human PCa cell lines. miR-636 promoted cellular invasion and migration, and may promote bone metastasis via targeting MBNL2, TNS1 and STAB1. In conclusion, we have successfully defined molecular signatures of bone metastasis in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.